Fig. 1: Proportion of ART initiation and death among PLHIV in China 2017–2019.

Proportion of ART initiation (a) and death (b) among PLHIV in China 2017–2019, stratified by initial ART regimen, ART antiretroviral therapy, NVP nevirapine, EFV efavirenz, DTG dolutegravir, LPV lopinavir, Others= darunavir, raltegravie, elvitegravir and rilpivirine.